Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Front Pharmacol ; 14: 1250383, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37705538

RESUMEN

Background: Humans are constantly exposed to various industrial, environmental, and endogenous particulates that result in inflammatory diseases. After being engulfed by immune cells, viz. Macrophages, such particulates lead to phagolysosomal dysfunction, eventually inducing pyroptosis, a form of cell death accompanied by the release of inflammatory mediators, including members of the interleukin (IL)-1 family. Phagolysosomal dysfunction results in the activation of the nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, an immune complex that induces pyroptosis upon exposure to various external stimuli. However, several particulates induce pyroptosis even if the NLRP3 inflammasome is inhibited; this indicates that such inhibition is not always effective in treating diseases induced by particulates. Therefore, discovery of drugs suppressing particulate-induced NLRP3-independent pyroptosis is warranted. Methods: We screened compounds that inhibit silica particle (SP)-induced cell death and release of IL-1α using RAW264.7 cells, which are incapable of NLRP3 inflammasome formation. The candidates were tested for their ability to suppress particulate-induced pyroptosis and phagolysosomal dysfunction using mouse primary macrophages and alleviate SP-induced NLRP3-independent lung inflammation. Results: Several Src family kinase inhibitors, including dasatinib, effectively suppressed SP-induced cell death and IL-1α release. Furthermore, dasatinib suppressed pyroptosis induced by other particulates but did not suppress that induced by non-particulates, such as adenosine triphosphate. Dasatinib reduced SP-induced phagolysosomal dysfunction without affecting phagocytosis of SPs. Moreover, dasatinib treatment strongly suppressed the increase in IL-1α levels and neutrophil counts in the lungs after intratracheal SP administration. Conclusion: Dasatinib suppresses particulate-induced pyroptosis and can be used to treat relevant inflammatory diseases.

2.
Int Immunol ; 34(10): 505-518, 2022 09 09.
Artículo en Inglés | MEDLINE | ID: mdl-35759801

RESUMEN

Nod-like receptor family pyrin domain-containing 3 (NLRP3) is a cytosolic innate immune receptor that senses organelle dysfunction induced by various stimuli, such as infectious, environmental, metabolic and drug stresses. Upon activation, NLRP3 forms an inflammasome with its adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1, to trigger the release of inflammatory cytokines. The development of effective anti-inflammatory drugs targeting the NLRP3 inflammasome is in high demand as its aberrant activation often causes inflammatory diseases. Here, we found that nanaomycin A (NNM-A), a quinone-based antibiotic isolated from Streptomyces, effectively inhibited NLRP3 inflammasome-mediated inflammatory responses induced by imidazoquinolines, including imiquimod. Interestingly, its epoxy derivative nanaomycin E (NNM-E) showed a comparable inhibitory effect against the NLRP3 inflammasome-induced release of interleukin (IL)-1ß and IL-18 from macrophages, with a much lower toxicity than NNM-A. NNM-E inhibited ASC oligomerization and caspase-1 cleavage, both of which are hallmarks of NLRP3 inflammasome activation. NNM-E reduced mitochondrial damage and the production of reactive oxygen species, thereby preventing the activation of the NLRP3 inflammasome. NNM-E treatment markedly alleviated psoriasis-like skin inflammation induced by imiquimod. Collectively, NNM-E inhibits NLRP3 inflammasome activation by preventing mitochondrial dysfunction with little toxicity and showed an anti-inflammatory effect in vivo. Thus, NNM-E could be a potential lead compound for developing effective and safe anti-inflammatory agents for the treatment of NLRP3 inflammasome-mediated inflammatory diseases.


Asunto(s)
Inflamasomas , Proteína con Dominio Pirina 3 de la Familia NLR , Caspasa 1/metabolismo , Imiquimod/metabolismo , Imiquimod/farmacología , Interleucina-1beta/metabolismo , Mitocondrias/metabolismo , Naftoquinonas
3.
Int Immunol ; 34(10): 493-504, 2022 09 09.
Artículo en Inglés | MEDLINE | ID: mdl-35639943

RESUMEN

The human body is exposed to various particulates of industrial, environmental, or endogenous origin. Invading or intrinsic particulates can induce inflammation by aberrantly activating the immune system, thereby causing crystallopathies. When immune cells such as macrophages phagocytose the particulates, their phagolysosomal membranes undergo mechanical damage, eventually leading to pyroptotic cell death accompanied by the release of inflammatory cytokines, including interleukin (IL)-1α and IL-1ß. The nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is responsible for particulate-induced IL-1ß release and is therefore regarded as a potential therapeutic target for inflammation-mediated crystallopathies. However, IL-1α is released after particulate stimulation in an NLRP3 inflammasome-independent manner and plays a critical role in disease development. Therefore, drugs that exert potent anti-inflammatory effects by comprehensively suppressing particulate-induced responses, including IL-1ß release and IL-1α release, should be developed. Here, we found that oridonin, a diterpenoid isolated from Isodon japonicus HARA, strongly suppressed particulate-induced cell death, accompanied by the release of IL-1α and IL-1ß in mouse and human macrophages. Oridonin reduced particulate-induced phagolysosomal membrane damage in macrophages without affecting phagocytosis of particulates. Furthermore, oridonin treatment markedly suppressed the symptoms of silica particle-induced pneumonia, which was attributed to the release of IL-1α independently of NLRP3. Thus, oridonin is a potential lead compound for developing effective therapeutics for crystallopathies attributed to NLRP3-dependent as well as NLRP3-independent inflammation.


Asunto(s)
Diterpenos de Tipo Kaurano , Interleucina-1beta , Pulmón , Proteína con Dominio Pirina 3 de la Familia NLR , Material Particulado , Neumonía , Animales , Diterpenos de Tipo Kaurano/farmacología , Diterpenos de Tipo Kaurano/uso terapéutico , Humanos , Inflamasomas/efectos de los fármacos , Inflamasomas/inmunología , Interleucina-1beta/antagonistas & inhibidores , Interleucina-1beta/metabolismo , Pulmón/efectos de los fármacos , Pulmón/inmunología , Ratones , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Material Particulado/toxicidad , Neumonía/inducido químicamente , Neumonía/tratamiento farmacológico , Neumonía/inmunología
4.
Comput Intell Neurosci ; 2021: 9963322, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34035802

RESUMEN

Face detection remains a challenging problem due to the high variability of scale and occlusion despite the strong representational power of deep convolutional neural networks and their implicit robustness. To handle hard face detection under extreme circumstances especially tiny faces detection, in this paper, we proposed a multiscale Hybrid Pyramid Convolutional Network (HPCNet), which is a one-stage fully convolutional network. Our HPCNet consists of three newly presented modules: firstly, we designed the Hybrid Dilated Convolution (HDC) module to replace the fully connected layers in VGG16, which enlarges receptive field and reduces its loss of local information; secondly, we constructed the Hybrid Feature Pyramid (HFP) to combine semantic information from higher layers together with details from lower layers; and thirdly, to deal with the problem of occlusion and blurring effectively, we introduced Context Information Extractor (CIE) in HPCNet. In addition, we presented an improved Online Hard Example Mining (OHEM) strategy, which can enhance the average precision of face detection by balancing the number of positive and negative samples. Our method has achieved an accuracy of 0.933, 0.924, and 0.848 on the Easy, Medium, and Hard subset of WIDER FACE, respectively, which surpasses most of the advanced algorithms.


Asunto(s)
Algoritmos , Redes Neurales de la Computación , Rotación , Semántica
5.
Cell Rep ; 25(11): 3086-3098.e3, 2018 12 11.
Artículo en Inglés | MEDLINE | ID: mdl-30540941

RESUMEN

Mediator of IRF3 activation (MITA), also known as stimulator of interferon genes (STING), plays a vital role in the innate immune responses to cytosolic dsDNA. The trafficking of MITA from the ER to perinuclear vesicles is necessary for its activation of the downstream molecules, which lead to the production of interferons and pro-inflammatory cytokines. However, the exact mechanism of MITA activation remains elusive. Here, we report that transmembrane emp24 protein transport domain containing 2 (TMED2) potentiates DNA virus-induced MITA signaling. The suppression or deletion of TMED2 markedly impairs the production of type I IFNs upon HSV-1 infection. TMED2-deficient cells harbor greater HSV-1 load than the control cells. Mechanistically, TMED2 associates with MITA only upon viral stimulation, and this process potentiates MITA activation by reinforcing its dimerization and facilitating its trafficking. These findings suggest an essential role of TMED2 in cellular IFN responses to DNA viruses.


Asunto(s)
Virus ADN/fisiología , Interferones/metabolismo , Proteínas de la Membrana/metabolismo , Multimerización de Proteína , Vesículas Cubiertas por Proteínas de Revestimiento/metabolismo , Citosol/metabolismo , ADN/metabolismo , Retículo Endoplásmico/metabolismo , Aparato de Golgi/metabolismo , Células HEK293 , Herpesvirus Humano 1/fisiología , Humanos , Inmunidad Innata , Transporte de Proteínas , Transducción de Señal , Células THP-1 , Proteínas de Transporte Vesicular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...